Medically reviewed by Brendan Camp, MD Hidradenitis suppurativa (HS) is a chronic (long-term) condition that causes painful ...

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

Secukinumab is under clinical development by Novartis and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

From public campaigns featuring Cyndi Lauper to ads with dinosaurs, MM+M compiles the best public marketing campaigns from ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Novartis AG (NYSE:NVS), based in Basel, Switzerland, is a global healthcare company specializing in developing, manufacturing, and marketing prescription and generic drugs, as well as eye care ...

We recently compiled a list of the 12 Cheap Healthcare Stocks to Buy Heading into 2025. In this article, we are going to take ...